Baseline patient and joint characteristics
| Patient characteristic . | Median (IQR) or n (%) . | |||
|---|---|---|---|---|
| N | 26 | |||
| Age, y | 21 (17-24) | |||
| Severe hemophilia | 16 (62) | |||
| Prophylactic treatment | 16 (62); 15 severe and 1 moderate hemophilia patient | |||
| Current dose of prophylaxis, IU/wk | 3000 (3000-3563) | |||
| AJBR (knees and ankles) | 0.5 (0.2-1.2) | |||
| Clinical function (HJHS) at joint level | 0 (0-1) | |||
| Pettersson score at joint level | 0 (0-0) | |||
| Patient characteristic . | Median (IQR) or n (%) . | |||
|---|---|---|---|---|
| N | 26 | |||
| Age, y | 21 (17-24) | |||
| Severe hemophilia | 16 (62) | |||
| Prophylactic treatment | 16 (62); 15 severe and 1 moderate hemophilia patient | |||
| Current dose of prophylaxis, IU/wk | 3000 (3000-3563) | |||
| AJBR (knees and ankles) | 0.5 (0.2-1.2) | |||
| Clinical function (HJHS) at joint level | 0 (0-1) | |||
| Pettersson score at joint level | 0 (0-0) | |||
| Joint characteristic . | Severe hemophilia on prophylaxis . | Moderate hemophilia treated on demand . | Overall* . | P† . |
|---|---|---|---|---|
| N | 59 (30 knees, 29 ankles) | 36 (18 knees, 18 ankles) | 100 (52 knees, 48 ankles) | |
| History of joint bleeding | 48 (81%); 22 knees, 26 ankles | 30 (83%); 15 knees, 15 ankles | 82 (82%); 40 knees, 42 ankles | .85 |
| Pettersson score 1-3 | 5 (8%); 1 knee, 4 ankles | 2 (6%); 1 knee, 1 ankle | 7 (7%); 2 knees, 5 ankles | .50 |
| MRI score ≥1 | 21 (36%); 8 knees, 13 ankles | 17 (47%); 6 knees, 11 ankles | 39 (39%); 15 knees, 24 ankles | .35 |
| MRI findings | ||||
| Effusion | 15 (25%); 7 knees, 8 ankles | 7 (19%); 4 knees, 3 ankles | 23 (23%); 12 knees, 11 ankles | .63 |
| Synovial hypertrophy | 8 (14%); 1 knee, 7 ankles | 8 (22%); 1 knee, 7 ankles | 16 (16%); 2 knees, 14 ankles | .27 |
| Hemosiderin deposits | 8 (14%); 1 knee, 7 ankles | 8 (22%); 1 knee, 7 ankles | 16 (16%); 2 knees, 14 ankles | .34 |
| Surface erosions | 4 (7%); 1 knee, 3 ankles | 3 (8%); 1 knee, 2 ankles | 7 (7%); 2 knees, 5 ankles | .80 |
| Subchondral cysts | 3 (5%); 1 knee, 2 ankles | 2 (6%); 0 knees, 2 ankles | 5 (5%); 1 knee, 4 ankles | .91 |
| Cartilage degradation | 4 (7%); 1 knee, 3 ankles | 5 (14%); 2 knees, 3 ankles | 9 (9%); 3 knees, 6 ankles | .30 |
| Joint characteristic . | Severe hemophilia on prophylaxis . | Moderate hemophilia treated on demand . | Overall* . | P† . |
|---|---|---|---|---|
| N | 59 (30 knees, 29 ankles) | 36 (18 knees, 18 ankles) | 100 (52 knees, 48 ankles) | |
| History of joint bleeding | 48 (81%); 22 knees, 26 ankles | 30 (83%); 15 knees, 15 ankles | 82 (82%); 40 knees, 42 ankles | .85 |
| Pettersson score 1-3 | 5 (8%); 1 knee, 4 ankles | 2 (6%); 1 knee, 1 ankle | 7 (7%); 2 knees, 5 ankles | .50 |
| MRI score ≥1 | 21 (36%); 8 knees, 13 ankles | 17 (47%); 6 knees, 11 ankles | 39 (39%); 15 knees, 24 ankles | .35 |
| MRI findings | ||||
| Effusion | 15 (25%); 7 knees, 8 ankles | 7 (19%); 4 knees, 3 ankles | 23 (23%); 12 knees, 11 ankles | .63 |
| Synovial hypertrophy | 8 (14%); 1 knee, 7 ankles | 8 (22%); 1 knee, 7 ankles | 16 (16%); 2 knees, 14 ankles | .27 |
| Hemosiderin deposits | 8 (14%); 1 knee, 7 ankles | 8 (22%); 1 knee, 7 ankles | 16 (16%); 2 knees, 14 ankles | .34 |
| Surface erosions | 4 (7%); 1 knee, 3 ankles | 3 (8%); 1 knee, 2 ankles | 7 (7%); 2 knees, 5 ankles | .80 |
| Subchondral cysts | 3 (5%); 1 knee, 2 ankles | 2 (6%); 0 knees, 2 ankles | 5 (5%); 1 knee, 4 ankles | .91 |
| Cartilage degradation | 4 (7%); 1 knee, 3 ankles | 5 (14%); 2 knees, 3 ankles | 9 (9%); 3 knees, 6 ankles | .30 |
Four ankles with a baseline Pettersson score ≥4 were excluded.
Including 2 joints of 1 patient with severe hemophilia treated on demand, and 3 joints of 1 patient with moderate hemophilia on prophylaxis.
P value for comparison of patients with severe hemophilia on prophylaxis/patient with moderate hemophilia treated on demand, adjusted for clustering of joints within patients.